Suchergebnisse - (Subject:"O3J8G9O825")

PubPharm (282)

1

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1 : week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

enthalten in: The lancet. HIV | 2024

von Orkin, C. | Molina, J. | Cahn, P. | +112

2

Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study) : an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial

enthalten in: The lancet. HIV | 2024

von Bekker, A. | Salvadori, N. | Rabie, H. | +10

ErratumIn: Lancet HIV. 2024 Apr 5;:. - PMID 38588690

3

Short-term toxicity assessment of combined use of zidovudine, lamivudine and lopinavir/ritonavir in vitro and in vivo

enthalten in: Basic & clinical pharmacology & toxicology | 2023

von Wen, P. | Ge, X. | Wang, Y. | +17

4

Quantification of nine antiretroviral drugs in cerebrospinal fluid : An approach to overcome sample collection tube adsorption

enthalten in: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences | 2023

von Mykris, T. | Weinhold, J. | Winchester, L. | +4

5

HIV-1 genotypic profiling ensures effective response to third-line antiretroviral therapy in Cameroon

enthalten in: Medicine | 2023

von Mbouyap, P. | Fokam, J. | Ngoufack Jagni Semengue, E. | +12

6

Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon : Children at high risk of virological failure due to the lowly transition in pediatrics

enthalten in: Medicine | 2023

von Fokam, J. | Nka, A. | Mamgue Dzukam, F. | +34

7

Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia : a pilot study

enthalten in: The Journal of antimicrobial chemotherapy | 2022

von Blanco, J. | Rojas, J. | de Lazzari, E. | +10

8

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA) : week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

enthalten in: The lancet. HIV | 2022

von Paton, N. | Musaazi, J. | Kityo, C. | +101

CommentIn: Lancet HIV. 2022 Jun;9(6):e368-e369. - PMID 35460602

9

Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates : PETITE Study

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2022

von Bekker, A. | Rabie, H. | Salvadori, N. | +12

10

Characterization of HIV-1 drug resistance among patients with failure of second-line combined antiretroviral therapy in central Ethiopia

enthalten in: HIV medicine | 2022

von Tufa, T. | Fuchs, A. | Orth, H. | +11

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[29]